• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖

Obesity.

机构信息

Anschutz Health and Wellness Center, and Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, Colorado (A.H.G.); Anschutz Health and Wellness Center, and Division of Endocrinology, University of Colorado School of Medicine, Aurora, Colorado (V.A.C.); Anschutz Health and Wellness Center, and Department of Family Medicine, University of Colorado School of Medicine, Aurora, Colorado (J.M.T.).

出版信息

Ann Intern Med. 2024 May;177(5):ITC65-ITC80. doi: 10.7326/AITC202405210. Epub 2024 May 14.

DOI:10.7326/AITC202405210
PMID:38739920
Abstract

Obesity is a common condition and a major cause of morbidity and mortality. Fortunately, weight loss treatment can reduce obesity-related complications. This review summarizes the evidence-based strategies physicians can employ to identify, prevent, and treat obesity, including best practices to diagnose and counsel patients, to assess and address the burden of weight-related disease including weight stigma, to address secondary causes of weight gain, and to help patients set individualized and realistic weight loss goals and an effective treatment plan. Effective treatments include lifestyle modification and adjunctive therapies such as antiobesity medications and metabolic and bariatric surgery.

摘要

肥胖是一种常见病症,也是发病率和死亡率的主要原因之一。幸运的是,减肥治疗可以减少肥胖相关并发症。本综述总结了医生可以采用的循证策略,以识别、预防和治疗肥胖,包括诊断和咨询患者的最佳实践,评估和解决与体重相关的疾病负担,包括体重耻辱感,解决体重增加的次要原因,并帮助患者设定个性化和现实的减肥目标和有效的治疗计划。有效的治疗方法包括生活方式的改变和辅助疗法,如抗肥胖药物和代谢与减重手术。

相似文献

1
Obesity.肥胖
Ann Intern Med. 2024 May;177(5):ITC65-ITC80. doi: 10.7326/AITC202405210. Epub 2024 May 14.
2
Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.体重减轻与生活方式治疗、药物治疗和减重手术预防和治疗 2 型糖尿病:作用机制。
Curr Obes Rep. 2015 Jun;4(2):287-302. doi: 10.1007/s13679-015-0155-x.
3
Approach to Obesity Treatment in Primary Care: A Review.基层医疗中肥胖治疗方法:综述。
JAMA Intern Med. 2024 Jul 1;184(7):818-829. doi: 10.1001/jamainternmed.2023.8526.
4
Update on Endoscopic Treatments for Obesity.肥胖症内镜治疗的最新进展
Curr Obes Rep. 2024 Jun;13(2):364-376. doi: 10.1007/s13679-024-00551-6.
5
Treating the Chronic Disease of Obesity.治疗肥胖这一慢性疾病。
Med Clin North Am. 2021 Nov;105(6):983-1016. doi: 10.1016/j.mcna.2021.06.005.
6
Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery.肥胖症药物治疗进展述评:代谢手术多模式治疗方法的启示。
Obes Surg. 2019 Dec;29(12):4095-4104. doi: 10.1007/s11695-019-04206-7.
7
What is Obesity?: Definition as a Disease, with Implications for Care.肥胖是什么?作为一种疾病的定义,及其对治疗的影响。
Gastroenterol Clin North Am. 2023 Jun;52(2):261-275. doi: 10.1016/j.gtc.2023.03.001. Epub 2023 Apr 7.
8
Treatment modalities of obesity: what fits whom?肥胖的治疗方式:哪种适合谁?
Diabetes Care. 2008 Feb;31 Suppl 2:S269-77. doi: 10.2337/dc08-s265.
9
Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery.降低心脏代谢危险因素的基础:通过药物治疗或减肥手术实现并维持体重减轻
Clin Cornerstone. 2008;9(1):41-8; discussion 49-51. doi: 10.1016/s1098-3597(08)60027-7.
10
Best Practices in the Management of Overweight and Obesity.超重和肥胖管理的最佳实践。
Med Clin North Am. 2021 Jan;105(1):149-174. doi: 10.1016/j.mcna.2020.08.018. Epub 2020 Nov 7.

引用本文的文献

1
Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization.肥胖作为一种慢性疾病:对不断演变的定义、管理策略及心血管代谢优先事项的叙述性综述
Adv Ther. 2025 Sep 5. doi: 10.1007/s12325-025-03352-y.
2
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors.早期体重增加作为接受劳拉替尼和其他ALK酪氨酸激酶抑制剂治疗的非小细胞肺癌患者最大体重增加增加的风险因素。
JTO Clin Res Rep. 2025 Jun 30;6(9):100870. doi: 10.1016/j.jtocrr.2025.100870. eCollection 2025 Sep.
3
Nonlinear relationship between body roundness index and prevalence of rheumatoid arthritis in American adults.
美国成年人身体圆润度指数与类风湿关节炎患病率之间的非线性关系。
Front Nutr. 2025 Jul 18;12:1585318. doi: 10.3389/fnut.2025.1585318. eCollection 2025.
4
Development and Validation of Body Mass Index-Specific Waist Circumference Thresholds in Postmenopausal Women : A Prospective Cohort Study.绝经后女性特定体重指数的腰围阈值的制定与验证:一项前瞻性队列研究
Ann Intern Med. 2025 Jul 8. doi: 10.7326/ANNALS-24-00713.
5
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.利拉鲁肽、司美格鲁肽或替尔泊肽停药后的体重反弹:随机研究的叙述性综述
J Clin Med. 2025 May 28;14(11):3791. doi: 10.3390/jcm14113791.
6
A Systematic Bibliometric Analysis of Cardiovascular Disease Risk in Obesity (2014-2024).肥胖与心血管疾病风险的系统文献计量分析(2014 - 2024年)
J Multidiscip Healthc. 2025 Jun 7;18:3233-3255. doi: 10.2147/JMDH.S504022. eCollection 2025.
7
Impact of the Triglyceride-Glucose index on all-cause and cardiovascular mortalities across different metabolic health and obesity statuses in US adults.甘油三酯-葡萄糖指数对美国成年人不同代谢健康和肥胖状态下全因死亡率和心血管死亡率的影响。
BMC Public Health. 2025 May 14;25(1):1767. doi: 10.1186/s12889-025-22901-2.
8
Influence of Body Mass Index (BMI) and Waist-Hip Ratio (WHR) on Selected Semen Parameters.体重指数(BMI)和腰臀比(WHR)对选定精液参数的影响。
Int J Mol Sci. 2025 Apr 25;26(9):4089. doi: 10.3390/ijms26094089.
9
The Median Effective Dose of Ciprofol Combined with Sufentanil for Inhibiting Responses to Gastroscope Insertion in Obese Patients: A Prospective, Single-Center Study.丙泊酚联合舒芬太尼抑制肥胖患者胃镜插入反应的半数有效剂量:一项前瞻性单中心研究
Drug Des Devel Ther. 2025 May 1;19:3577-3587. doi: 10.2147/DDDT.S494972. eCollection 2025.
10
Supplementation of mixed alleviates metabolic impairment, inflammation, and dysbiosis of the gut microbiota in an obese mouse model.混合补充剂可减轻肥胖小鼠模型中的代谢损伤、炎症及肠道微生物群失调。
Front Nutr. 2025 Mar 26;12:1554996. doi: 10.3389/fnut.2025.1554996. eCollection 2025.